The excitatory amino acid transporters (EAATs) are expressed throughout the central nervous system, where they are responsible for the reuptake of the excitatory neurotransmitter (
S)-glutamate (Glu).
(1) Recently, we have reported the discovery of the first subtype selective EAAT1 inhibitor 2-amino-4-(4-methoxyphenyl)-7-(naphthalen-1-yl)-5-oxo-5,6,7,8-tetrahydro-4
H-chromene-3-carbonitrile (UCPH-101) (
1b) and presented an introductory structure−activity relationship (SAR) study.
(2) Here, we present a detailed SAR by the design, synthesis, and pharmacological evaluation of analogues
1g−
1t. By comparison of potencies of
1b,
1h, and
1i versus
1j, it is evident that potency is largely influenced by the chemical nature of the R
1 substituent. The study also demonstrates that any chemical change of the functional groups or a change to the parental scaffold results in the complete loss of inhibitory activity of the compounds at EAAT1. Finally, a bioavailability study of UCPH-101 determined the half-life to be 30 min in serum (rats) but also that it was not able to penetrate the blood−brain barrier to any significant degree.